HRP20230109T1 - Postupci pripreme 18f-obilježenih psma-usmjerenih sredstava za pet snimanje i dijagnostički postupci sa njima - Google Patents
Postupci pripreme 18f-obilježenih psma-usmjerenih sredstava za pet snimanje i dijagnostički postupci sa njima Download PDFInfo
- Publication number
- HRP20230109T1 HRP20230109T1 HRP20230109TT HRP20230109T HRP20230109T1 HR P20230109 T1 HRP20230109 T1 HR P20230109T1 HR P20230109T T HRP20230109T T HR P20230109TT HR P20230109 T HRP20230109 T HR P20230109T HR P20230109 T1 HRP20230109 T1 HR P20230109T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- image
- formula
- group
- nitrobenzyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 18
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 239000012216 imaging agent Substances 0.000 title 1
- -1 [18F]-fluoro group Chemical group 0.000 claims 45
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 claims 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims 6
- 229960005235 piperonyl butoxide Drugs 0.000 claims 6
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000002125 Hemangioendothelioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 125000005210 alkyl ammonium group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 201000005443 oral cavity cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000008006 pharynx cancer Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2416—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Postupak pripreme formule (I)
[image]
ili njene farmaceutski prihvatljive soli, postupak je naznačen time što sadrži dovođenje u kontakt spoja formule (III):
[image]
ili njegove farmaceutski prihvatljive soli sa izvorom fluorida ili radiofluorida, pri čemu
L je linker koji sadrži funkcionalnu grupu formule -NH-CH2CH2-(OCH2CH2-)y-C(O)- ili grupu formule
[image]
pri čemu
y je 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12;
m je 1, 2, 3, ili 4;
svako n je nezavisno 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12;
R1 je fenil ili piridil; pri čemu je fenil ili piridil supstituiran sa [F]- ili [18F]-fluoro grupom i izborno supstituiran sa drugom grupom koja je odabrana od halogena, cijano, i nitro;
svako R2 je nezavisno vodik ili C1-C6 alkil;
R3 je fenil ili piridil; pri čemu je fenil ili piridil supstituiran sa odlazećom grupom i izborno supstituiran sa drugom grupom koja je odabrana od halogena, cijano, i nitro; i
svako R je nezavisno vodik ili zaštitna grupa koja je odabrana iz grupe koja se sastoji od alkila, alkenila, haloalkila, benzila, trifenilmetila (tritila), difenilmetila, o-nitrobenzila, 2,4,6-trimetilbenzila, p-bromobenzila, p-nitrobenzila, p-metoksibenzila (PMB), 2,6-dimetoksibenzila, 4-(metilsulfinil)benzila, 4-sulfobenzila, 4-azidometoksibenzila, i piperonila, poželjno koja je odabrana iz grupe koja se sastoji od metila, etila, propila, izopropila, terc-butila, alila, trifluorometila, trifluoroetila, benzila, trifenilmetila (tritila), difenilmetila, o-nitrobenzila, 2,4,6-trimetilbenzila, p-bromobenzila, p-nitrobenzila, p-metoksibenzila (PMB), 2,6-dimetoksibenzila, 4-(metilsulfinil)benzila, 4-sulfobenzila, 4-azidometoksi-benzila, i piperonila;
pod uvjetom da kada je L grupa formule
[image]
m·(n+2) je veće od ili jednako 3 i manje od ili jednako 21.
2. Postupak pripreme formule (I)
[image]
ili njene farmaceutski prihvatljive soli, postupak je naznačen time što sadrži dovođenje u kontakt spoja formule (II),
[image]
ili njegove farmaceutski prihvatljive soli sa spojem formule (IV),
[image]
pri čemu
L je linker koji sadrži funkcionalnu grupu formule -NH-CH2CH2-(OCH2CH2-)y-C(O)- ili grupu formule
[image]
pri čemu
y je 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12;
m je 1, 2, 3, ili 4;
svako n je nezavisno 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12;
R1 je fenil ili piridil; pri čemu je fenil ili piridil supstituiran sa [F]- ili [18F]-fluoro grupom i izborno supstituiran sa drugom grupom koja je odabrana od halogena, cijano, i nitro;
svako R2 je nezavisno vodik ili C1-C6 alkil;
R5 je R1; i
svako R je nezavisno vodik ili zaštitna grupa koja je odabrana iz grupe koja se sastoji od alkila, alkenila, haloalkila, benzila, trifenilmetila (tritila), difenilmetila, o-nitrobenzila, 2,4,6-trimetilbenzila, p-bromobenzila, p-nitrobenzila, p-metoksibenzila (PMB), 2,6-dimetoksibenzila, 4-(metilsulfinil)benzila, 4-sulfobenzila, 4-azidometoksibenzila, i piperonila, poželjno koja je odabrana iz grupe koja se sastoji od metila, etila, propila, izopropila, terc-butila, alila, trifluorometila, trifluoroetila, benzila, trifenilmetila (tritila), difenilmetila, o-nitrobenzila, 2,4,6-trimetilbenzila, p-bromobenzila, p-nitrobenzila, p-metoksibenzila (PMB), 2,6-dimetoksibenzila, 4-(metilsulfinil)benzila, 4-sulfobenzila, 4-azidometoksi-benzila, i piperonila;
pod uvjetom da kada je L grupa formule
[image]
m·(n+2) je veće od ili jednako 3 i manje od ili jednako 21.
3. Postupak za detektiranje i/ili identificiranje stanica koje prezentiraju PSMA naznačen time što sadrži dovođenje u kontakt stanice za koju se sumnja da prezentiraju PSMA sa spojem formule (I)
[image]
ili njegovom farmaceutski prihvatljivom solju, pri čemu
L je linker koji sadrži funkcionalnu grupu formule -NH-CH2CH2-(OCH2CH2-)y-C(O) ili grupu formule
[image]
pri čemu
y je 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12;
m je 1, 2, 3, ili 4;
svako n je nezavisno 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ili 12;
R1 je fenil ili piridil; pri čemu je fenil ili piridil supstituiran sa [F]- ili [18F]-fluoro grupom i izborno supstituiran sa drugom grupom koja je odabrana od halogena, cijano, i nitro;
svako R2 je nezavisno vodik ili C1-C6 alkil; i
svako R je nezavisno vodik ili zaštitna grupa koja je odabrana iz grupe koja se sastoji od alkila, alkenila, haloalkila, benzila, trifenilmetila (tritila), difenilmetila, o-nitrobenzila, 2,4,6-trimetilbenzila, p-bromobenzila, p-nitrobenzila, p-metoksibenzila (PMB), 2,6-dimetoksibenzila, 4-(metilsulfinil)benzila, 4-sulfobenzila, 4-azidometoksibenzila, i piperonila, poželjno koja je odabrana iz grupe koja se sastoji od metila, etila, propila, izopropila, terc-butila, alila, trifluorometila, trifluoroetila, benzila, trifenilmetila (tritila), difenilmetila, o-nitrobenzila, 2,4,6-trimetilbenzila, p-bromobenzila, p-nitrobenzila, p-metoksibenzila (PMB), 2,6-dimetoksibenzila, 4-(metilsulfinil)benzila, 4-sulfobenzila, 4-azidometoksi-benzila, i piperonila;
pod uvjetom da kada je L grupa formule
[image]
m·(n+2) je veće od ili jednako 3 i manje od ili jednako 21.
4. Postupak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što je spoj formule (Ic):
[image]
ili njegova farmaceutski prihvatljiva sol.
5. Postupak prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što
(i) svako R je vodik; i/ili
(ii) svako R2 je vodik.
6. Postupak prema bilo kojem od patentnih zahtjeva 1-5, naznačen time što je m 1 ili 2.
7. Postupak prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što je spoj formule (Id):
[image]
ili njegova farmaceutski prihvatljiva sol.
8. Postupak prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što je R1:
[image]
pri čemu
X je vodik ili kloro; i
Y je N ili CH.
9. Postupak prema patentnom zahtjevu 8, naznačen time što
(i) X je vodik i Y je CH;
(ii) X je vodik i Y je N;
(iii) X je kloro i Y je N; ili
(iv) X je kloro i Y je CH.
10. Postupak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što je spoj formule (I):
[image]
[image]
[image]
[image]
ili njihova farmaceutski prihvatljiva sol.
11. Postupak prema patentnom zahtjevu 1 ili 2, ili bilo kojem od patentnih zahtjeva 4-10 kada ovise od patentnog zahtjeva 1 ili 2, naznačen time što je izvor radiofluorida Na18F, K18F, Cs18F, tetra(C1-C6)alkilamonij18F fluorid, ili tetra(C1-C6)alkilfosfonij 18F fluorid.
12. Postupak prema patentnom zahtjevu 1 ili 2, ili bilo kojem od patentnih zahtjeva 4-10 kada ovise od patentnog zahtjeva 1 ili 2, naznačen time što je izvor fluorida NaF, KF, CsF, tetra(C1-C6)alkilamonij fluorid, ili tetra(C1-C6)alkilfosfonij fluorid.
13. Postupak prema patentnom zahtjevu 3, ili bilo kojem od patentnih zahtjeva 4-10 kada ovise od patentnog zahtjeva 3, naznačen time što je stanica iz neoplazme.
14. Postupak prema patentnom zahtjevu 13, naznačen time što je neoplazma rak.
15. Postupak prema patentnom zahtjevu 14, naznačen time što je rak odabran od raka oka ili okularnog raka, rektalnog raka, raka debelog crijeva, raka vrata materice, raka prostate, raka dojke, raka mokraćnog mjehura, raka usne šupljine, benignih tumora, malignih tumora, raka želuca, raka jetre, raka gušterače, raka pluća, tijela materice, raka jajnika, raka prostate, raka testisa, renalnog raka, raka mozga (npr. gliomi), raka grla, melanoma kože, akutne limfocitne leukemije, akutne mijelogene leukemije, Ewingovog sarkoma, Kaposijevog sarkoma, karcinoma bazalnih stanica, karcinoma pločastih stanica, sitnostaničnog raka pluća, koriokarcinoma, rabdomiosarkoma, angiosarkoma, hemangioendotelioma, Wilmsovog tumora, neuroblastoma, raka usta/farinksa, raka jednjaka, raka larinksa, limfoma, neurofibromatoze, tuberozne skleroze, hemangioma, i limfangiogeneze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798108P | 2013-03-15 | 2013-03-15 | |
| EP19179758.8A EP3560937B1 (en) | 2013-03-15 | 2014-03-14 | Methods of preparing 18f-labeled psma-targeted pet imaging agents and diagnostic methods therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230109T1 true HRP20230109T1 (hr) | 2023-04-28 |
Family
ID=50639969
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230109TT HRP20230109T1 (hr) | 2013-03-15 | 2014-03-14 | Postupci pripreme 18f-obilježenih psma-usmjerenih sredstava za pet snimanje i dijagnostički postupci sa njima |
| HRP20191482 HRP20191482T1 (hr) | 2013-03-15 | 2019-08-16 | 18f-označeni psma ciljani pet reagensi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191482 HRP20191482T1 (hr) | 2013-03-15 | 2019-08-16 | 18f-označeni psma ciljani pet reagensi |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11554183B2 (hr) |
| EP (3) | EP2970345B1 (hr) |
| CN (2) | CN108558939B (hr) |
| AU (2) | AU2014228233B2 (hr) |
| CA (1) | CA2903131C (hr) |
| DK (2) | DK3560937T3 (hr) |
| ES (2) | ES2937955T3 (hr) |
| FI (1) | FI3560937T3 (hr) |
| HR (2) | HRP20230109T1 (hr) |
| HU (2) | HUE061402T2 (hr) |
| LT (2) | LT2970345T (hr) |
| PL (2) | PL2970345T3 (hr) |
| PT (2) | PT3560937T (hr) |
| RS (1) | RS64011B1 (hr) |
| SI (2) | SI3560937T1 (hr) |
| WO (1) | WO2014143736A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11078166B2 (en) | 2015-08-13 | 2021-08-03 | The Johns Hopkins University | Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof |
| EP3497108A1 (en) * | 2016-08-10 | 2019-06-19 | Cancer Targeted Technology LLC | Chelated psma inhibitors |
| US11963775B2 (en) | 2017-03-22 | 2024-04-23 | Safeop Surgical, Inc. | Medical systems and methods for detecting changes in electrophysiological evoked potentials |
| WO2018233798A1 (en) | 2017-06-20 | 2018-12-27 | ITM Isotopen Technologien München AG | NOVEL PSMA BINDING AGENTS AND USE THEREOF |
| US11629201B2 (en) | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| WO2020108753A1 (en) | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| WO2020224780A1 (en) | 2019-05-08 | 2020-11-12 | ITM Isotopen Technologien München AG | Para-aminohippuric acid (pah) as a renal protective substance |
| WO2021046233A1 (en) | 2019-09-03 | 2021-03-11 | Cancer Targeted Technology Llc | Chelate-containing psma inhibitors |
| WO2022096103A1 (en) | 2020-11-05 | 2022-05-12 | ITM Isotopen Technologien München AG | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| IL307381A (en) | 2021-04-02 | 2023-11-01 | Advanced Accelerator Applications | Diagnostic methods of prostate cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696185B2 (en) * | 2006-03-14 | 2010-04-13 | Cancer Targered Technology LLC | Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use |
| US8557776B2 (en) * | 2006-09-08 | 2013-10-15 | Bayer Pharma AG | Compounds and methods for 18F labeled agents |
| CN107382846B (zh) * | 2008-08-01 | 2021-07-06 | 约翰.霍普金斯大学 | Psma-结合剂及其用途 |
| WO2012064914A2 (en) * | 2010-11-12 | 2012-05-18 | Washington State University Research Foundation | Peptidomimetic inhibitors of psma |
| EP2721039B1 (en) * | 2011-06-15 | 2018-01-10 | Cancer Targeted Technology LLC | Chelated psma inhibitors |
| CN102757296B (zh) * | 2012-04-10 | 2014-11-19 | 中国科学院上海应用物理研究所 | 一种对化合物进行[18f]标记的方法 |
| WO2013173630A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Formulation of radiopharmaceuticals containing multiple acidic groups |
| WO2013173583A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Psma inhibitors |
-
2014
- 2014-03-14 US US14/774,371 patent/US11554183B2/en active Active
- 2014-03-14 WO PCT/US2014/027820 patent/WO2014143736A1/en active Application Filing
- 2014-03-14 ES ES19179758T patent/ES2937955T3/es active Active
- 2014-03-14 RS RS20230089A patent/RS64011B1/sr unknown
- 2014-03-14 CN CN201810256877.5A patent/CN108558939B/zh active Active
- 2014-03-14 HU HUE19179758A patent/HUE061402T2/hu unknown
- 2014-03-14 EP EP14721640.2A patent/EP2970345B1/en active Active
- 2014-03-14 FI FIEP19179758.8T patent/FI3560937T3/fi active
- 2014-03-14 CA CA2903131A patent/CA2903131C/en active Active
- 2014-03-14 LT LTEP14721640.2T patent/LT2970345T/lt unknown
- 2014-03-14 SI SI201432018T patent/SI3560937T1/sl unknown
- 2014-03-14 EP EP22215508.7A patent/EP4180438A1/en active Pending
- 2014-03-14 DK DK19179758.8T patent/DK3560937T3/da active
- 2014-03-14 ES ES14721640T patent/ES2743433T3/es active Active
- 2014-03-14 PL PL14721640T patent/PL2970345T3/pl unknown
- 2014-03-14 EP EP19179758.8A patent/EP3560937B1/en active Active
- 2014-03-14 PT PT191797588T patent/PT3560937T/pt unknown
- 2014-03-14 PL PL19179758.8T patent/PL3560937T3/pl unknown
- 2014-03-14 HU HUE14721640A patent/HUE046194T2/hu unknown
- 2014-03-14 PT PT14721640T patent/PT2970345T/pt unknown
- 2014-03-14 AU AU2014228233A patent/AU2014228233B2/en active Active
- 2014-03-14 HR HRP20230109TT patent/HRP20230109T1/hr unknown
- 2014-03-14 SI SI201431305T patent/SI2970345T1/sl unknown
- 2014-03-14 LT LTEP19179758.8T patent/LT3560937T/lt unknown
- 2014-03-14 CN CN201480021159.XA patent/CN105308056B/zh active Active
- 2014-03-14 DK DK14721640.2T patent/DK2970345T3/da active
-
2019
- 2019-05-22 AU AU2019203610A patent/AU2019203610B2/en active Active
- 2019-08-16 HR HRP20191482 patent/HRP20191482T1/hr unknown
-
2023
- 2023-01-04 US US18/149,981 patent/US20230144322A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230109T1 (hr) | Postupci pripreme 18f-obilježenih psma-usmjerenih sredstava za pet snimanje i dijagnostički postupci sa njima | |
| JP2019517487A5 (hr) | ||
| NZ707171A (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2016503799A5 (hr) | ||
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2013542218A5 (hr) | ||
| JO3413B1 (ar) | مشتقات نافثيريدين في صورة مضادات ألفا v بيتا 6 إنتيجرين لعلاج الأمراض الليفية e.g | |
| JP2016513660A5 (hr) | ||
| CY1119356T1 (el) | Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης | |
| PE20160862A1 (es) | Polimorfo de los inhibidores de la syk | |
| JP2015517574A5 (hr) | ||
| JP2017502940A5 (hr) | ||
| EA201591675A1 (ru) | Замещенные 7-азабициклы и их применение в качестве модуляторов рецепторов орексина | |
| JP2016534134A5 (hr) | ||
| HRP20211970T1 (hr) | Policiklički derivati amida kao inhibitori cdk9 | |
| JO3811B1 (ar) | مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| PH12015502047A1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| GEP201606507B (en) | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors | |
| TN2015000054A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| HRP20192101T1 (hr) | Inhibitori ezh2 | |
| JP2013502441A5 (hr) | ||
| JP2016531126A5 (hr) |